Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2008

01-01-2008 | Brief Report

The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept

Authors: Andrea Golmia, Beni Grinblat, Eduardo Finger, Claudia Klieman, Fernanda Assir, Morton Scheinberg

Published in: Clinical Rheumatology | Issue 1/2008

Login to get access

Abstract

In this case report, we present the first report of erythema elevatum diutinum after treatment of juvenile idiopathic arthritis with abatacept. Although it could also be coincidental, in our case, the appearance of vasculitis was not blocked by the simultaneous administration of a stimulation inhibitor, and alerts to the fact that as effective as a abatacept may be to control of the inflammatory articular symptoms, this might not translate into control of the disease.
Literature
1.
2.
Crowson AN, Mihm MC Jr, Magro CM (2003) Cutaneous vasculitis: a review. J Cutan Pathol 30:161–173PubMedCrossRef
3.
Woody CM, Lane JE, Davis LS (2005) Erythema elevatum diutinum in the setting of connective tissue disease and chronic bacterial infection. J Clin Rheumatol 11:98–104PubMedCrossRef
4.
Wahl CE, Bouldin MB, Gibson LE (2005) Erythema elevatum diutinum: clinical, histopathologic, and immunohistochemical characteristics of six patients. Am J Dermatopathol 27:397–400PubMedCrossRef
5.
Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, Prieur AM, Rider LG, Silverman E, Tsitsami E, Woo P, Giannini EH, Martini A (2003) Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 42:1452–1459CrossRef
Metadata
Title
The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept
Authors
Andrea Golmia
Beni Grinblat
Eduardo Finger
Claudia Klieman
Fernanda Assir
Morton Scheinberg
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0743-6

Other articles of this Issue 1/2008

Clinical Rheumatology 1/2008 Go to the issue

Original Article

Prevalence of ZAP-70, LAT, SLP-76, and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus

Brief Report

Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFα blocking agents in rheumatoid arthritis

Brief Report

Radiological aid to clinical diagnosis of Schnitzler’s syndrome: multimodality imaging approach

Original Article

HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies

Brief Report

Hepatitis C virus infection in Italian patients with fibromyalgia

Case Report

Association of HELLP syndrome with primary antiphospholipid syndrome—a case report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits